Adjuvant therapies improve breast cancer survival in older women

WORLDWIDE collaborative research shows that aromatase inhibitors and bisphosphonates improve survival of postmenopausal women with early breast cancer, while also reducing side effects, compared to other therapies.

Two studies published in The Lancet provide “really good evidence” that these cheap, generic drugs can reduce breast cancer mortality in postmenopausal women, says Richard Gray, lead statistician on both studies and professor of medical statistics at the University of Oxford. 

“The drugs are complementary,